Labor Market Pulse · Life Sciences · September 2026
Life Sciences Labor Market Report: VT NONMETROPOLITAN AREA — September 2026
Vermont's shrinking labor force collides with rising clinical pay.
Statewide labor force down roughly 2.2% year-over-year while nonmetro CRA pay jumps to a $136,574 median, far outpacing the $90,956 national figure.
Free archive edition. Published by WageScape as sent to subscribers; data as of September 2026.
Key indicators
- Vermont labor force change: -2.2% YoY — Driven mainly by retirements, not layoffs
- Nonmetro county unemployment range: 2.3%–3.2% — Addison/Caledonia low, Essex/Orleans high
- CRA advertised pay, metro vs. national: $136,574 vs $90,956 — Metro up significantly, outpaces national median
- Vermont statewide unemployment: 2.6% — Third-lowest in U.S. as of August 2026
Key takeaways
Vermont's labor force shrinkage is demographic, not economic.
Retirements, not layoffs, account for most of the roughly 2.2% annual labor force decline statewide. Life Sci leaders should plan headcount growth assuming the candidate pool keeps contracting regardless of hiring budget or market conditions.
Regulatory and CMC scarcity is a Vermont-specific build constraint.
Rocket Pharma's Director of Regulatory Affairs–CMC posting at $204K–$264K reflects a national bottleneck landing hard in a thin local market. Expect regulatory roles to require above-market offers or out-of-state recruiting regardless of CDMO availability nearby.
Local lab technician pay is falling even as national rates hold up.
Metro median advertised pay for Lab Technicians sits at $40,930, down significantly, against a national median of $47,402 also trending down moderately. Compressed entry-level lab wages may support internal QA staffing but risk turnover to neighboring metros or remote-friendlier employers.
Clinical Research Associate pay is rising sharply against a thin field.
Metro CRA median pay of $136,574 is up significantly and now exceeds the national median of $90,956 by a wide margin. A small local candidate pool combined with active CRO/CDMO demand (Charles River, Rocket Pharma) is pushing employers to bid well above national norms to fill clinical roles.
Median advertised pay by role — VT NONMETROPOLITAN AREA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $109,700 | $152,502 | $152,503 | Moderate decline | $131,354 |
| Clinical Research Associate | $123,155 | $136,574 | $138,772 | Significant increase | $90,956 |
| Lab Technician | $39,286 | $40,930 | $41,870 | Significant decline | $47,402 |
| Regulatory Affairs Specialist * | $86,099 | $95,902 | $100,000 | Stable | $104,000 |
| Clinical Data Manager | $83,968 | $101,447 | $108,998 | Significant decline | $123,031 |
| Biostatistician | $106,453 | $144,208 | $144,343 | Significant decline | $133,322 |
| Validation Engineer | — | — | — | No data | $108,377 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Vermont's nonmetro counties show a labor force contracting under structural pressure rather than cyclical softness — statewide labor force fell roughly 2.2% year-over-year through mid-2026, driven primarily by retirements rather than layoffs. County unemployment across nonmetro Vermont ranges narrow, from 2.3% in Addison and Caledonia to 3.2% in Essex and Orleans, leaving employers in gene therapy, contract research, and diagnostics competing for a shrinking, already-tight talent pool with no slack building anywhere nearby.
What it means
Shrinking labor supply across nonmetro Vermont counties means Life Sci employers cannot count on population growth or inbound migration to ease specialized hiring — Rocket Pharma's Winooski regulatory recruitment at $204K–$264K and Charles River's East Thetford contract operations both depend on a talent base that is structurally not growing. Build-vs-outsource tradeoffs tilt further toward CDMO/CRO partnerships for roles where statewide scarcity is acute (regulatory CMC, cell/gene specialists), while routine QA and clinical support functions remain more defensible to staff internally given compressed lower-end wage bands. Organizations should evaluate which regulatory and manufacturing roles justify premium retention investment locally versus which can shift to contract partners already embedded in the Vermont ecosystem.
Looking ahead
Potential inflection point: Vermont's Right to Collective Bargaining constitutional amendment appears on the November 2026 ballot with roughly 65% polling support. A pro-labor shift could reshape compensation negotiation dynamics for manufacturing and R&D staff at Vermont-based biotech and CDMO employers.
Emerging pressure point: UVM Health Network layoffs announced earlier in 2026 will not be felt until October, potentially releasing clinical and quality-adjacent talent into a market with almost no slack. Watch whether this cohort absorbs into Life Sci employers or exits the state entirely.
Worth watching: CRA and Biostatistician advertised pay are moving in opposite directions locally — CRA up significantly, Biostatistician down significantly to $144,208. Divergence this sharp across adjacent clinical functions warrants a fresh look at role-specific offers rather than blanket clinical pay adjustments.
Early indicator: Manufacturing WARN activity tied to Franklin County dairy processors signals continued erosion of Vermont's broader manufacturing base. Monitor whether displaced skilled production workers migrate toward biomanufacturing and CMC roles, a potential but unproven talent pipeline.
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.